{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fischer RJ"],"funding":["Intramural NIH HHS","Division of Intramural Research, National Institute of Allergy and Infectious Diseases","Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)"],"pagination":["5868"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8497486"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observe a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 do not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals do not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus can be detected in lungs of vaccinated animals. Histopathological evaluation shows extensive pulmonary pathology cau"],"journal":["Nature communications"],"pubmed_title":["ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7."],"pmcid":["PMC8497486"],"funding_grant_id":["NA","ZIA AI001179"],"pubmed_authors":["Long D","Munster VJ","Lambe T","Fischer RJ","Gilbert SC","Ricklefs S","de Wit E","Williamson BN","Schulz JE","Smith BJ","van Doremalen N","Yinda CK","Martens C","Saturday G","Adney DR","Thomas T","Holbrook MG","Port JR","Barbian K","Anzick SL"],"additional_accession":[]},"is_claimable":false,"name":"ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.","description":"We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observe a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 do not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals do not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus can be detected in lungs of vaccinated animals. Histopathological evaluation shows extensive pulmonary pathology cau","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-05-18T12:31:05.325Z","creation":"2025-05-18T12:31:05.325Z"},"accession":"S-EPMC8497486","cross_references":{"pubmed":["34620866"],"doi":["10.1038/s41467-021-26178-y"]}}